FindTrial
Sign In

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01169792
Enrollment
Unknown
Registered
2010-07-26
Start date
Unknown
Completion date
Unknown
Last updated
2010-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antineoplastic Agents, Breast Neoplasms, Survival Analysis, Therapeutic Uses

Keywords

Tamoxifen, Cytochrome P-450 CYP2D6, Polymorphism, Single nucleotide, Antineoplastic Agents, Hormonal

Brief summary

The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen. The investigators want to * evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and * analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.

Interventions

DRUGtamoxifen

Sponsors

Inje University
CollaboratorOTHER
Yonsei University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* age ≥ 18 years * Breast cancer patients who underwent surgery

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
The frequency of the genetic polymorphisms of CYP3A4/5 in breast cancer patients—
The frequency of the genetic polymorphisms of CYP2C19 in breast cancer patients—
The frequency of the genetic polymorphisms of CYP2D6 in breast cancer patients—

Secondary

MeasureTime frame
The association between the genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen therapy—
The association between the genetic polymorphisms of CYP3A4/5 and outcomes in breast cancer patients with tamoxifen therapy—
The association between the genetic polymorphisms of CYP2C19 and outcomes in breast cancer patients with tamoxifen therapy—

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026